The Finding of New In Vivo Metabolite Triptorelin (5-10) in Human Urine Using Liquid Chromatography Coupled with Ion Trap/Time-of-Flight Mass Spectrometry with Dimethyl Sulfoxide Additives in the Mobile Phase

Triptorelin and leuprorelin are synthetic gonadotrophin-releasing hormones (GnRH) that are on the World Anti-Doping Agency (WADA) list of prohibited substances. To investigate the possible in vivo metabolites of triptorelin and leuprorelin in humans compared to previously reported in vitro metabolites, excreted urine from five patients treated with either triptorelin or leuprorelin was analyzed by liquid chromatography coupled with ion trap/time-of-flight mass spectrometry (LC/MS-IT-TOF). The addition of dimethyl sulfoxide (DMSO) to the mobile phase was found to enhance the detection sensitivity of certain GnRH analogs. The method was validated, and the limit of detection (LOD) was found at 0.02−0.08 ng/mL. Using this method, a novel new metabolite of triptorelin was discovered in the urine of all subjects up to 1 month after triptorelin administration, but it was not observed in the urine of subjects before drug administration. The limit of detection was estimated to be 0.05 ng/mL. The structure of the metabolite, triptorelin (5-10), is proposed from bottom-up mass spectrometry analysis. The discovery of in vivo triptorelin (5-10) can possibly be used as supporting evidence of triptorelin misuse in athletes.

[1]  V. Fokin,et al.  Dual Electrospray Ionization Enhancement of Proteins Enabled by DMSO Supercharging Reagent. , 2021, Journal of the American Society for Mass Spectrometry.

[2]  C. S. Brian Chia.  A Review on the Metabolism of 25 Peptide Drugs , 2021, International Journal of Peptide Research and Therapeutics.

[3]  M. Mann,et al.  A beginner’s guide to mass spectrometry–based proteomics , 2020, The Biochemist.

[4]  Hong Yang,et al.  Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability. , 2018, Current drug metabolism.

[5]  I. Zvereva,et al.  Determination of GnRH and its synthetic analogues' abuse in doping control: Small bioactive peptide UPLC-MS/MS method extension by addition of in vitro and in vivo metabolism data; evaluation of LH and steroid profile parameter fluctuations as suitable biomarkers. , 2018, Drug testing and analysis.

[6]  P. Lasch,et al.  DMSO as a mobile phase additive enhances detection of ubiquitination sites by nano-LC-ESI-MS/MS. , 2018, Journal of mass spectrometry : JMS.

[7]  U. Kaiser,et al.  Gonadotropin regulation by pulsatile GnRH: Signaling and gene expression , 2017, Molecular and Cellular Endocrinology.

[8]  K. Deventer,et al.  DMSO Assisted Electrospray Ionization for the Detection of Small Peptide Hormones in Urine by Dilute-and-Shoot-Liquid-Chromatography-High Resolution Mass Spectrometry , 2017, Journal of The American Society for Mass Spectrometry.

[9]  C. Eyers,et al.  Evaluation of dimethyl sulfoxide (DMSO) as a mobile phase additive during top 3 label-free quantitative proteomics , 2015, International journal of mass spectrometry.

[10]  M. Thevis,et al.  Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin. , 2015, Drug testing and analysis.

[11]  A. Sharma,et al.  Gonadotropin-releasing hormone analogs: Understanding advantages and limitations , 2014, Journal of human reproductive sciences.

[12]  David Handelsman,et al.  Detection and effects on serum and urine steroid and LH of repeated GnRH analog (leuprolide) stimulation , 2014, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Ravi Amunugama,et al.  Bottom-Up Mass Spectrometry-Based Proteomics as an Investigative Analytical Tool for Discovery and Quantification of Proteins in Biological Samples. , 2013, Advances in wound care.

[14]  Bernhard Kuster,et al.  DMSO enhances electrospray response, boosting sensitivity of proteomic experiments , 2013, Nature Methods.

[15]  Hai Wu,et al.  Liquid chromatography coupled with time-of-flight and ion trap mass spectrometry for qualitative analysis of herbal medicines , 2011, Journal of pharmaceutical analysis.

[16]  Lian‐Wen Qi,et al.  Herbal medicine analysis by liquid chromatography/time-of-flight mass spectrometry. , 2009, Journal of chromatography. A.

[17]  M. Thevis,et al.  Mass spectrometric determination of gonadotrophin-releasing hormone (GnRH) in human urine for doping control purposes by means of LC-ESI-MS/MS. , 2008, Journal of mass spectrometry : JMS.

[18]  O. Jensen,et al.  Solid phase extraction-liquid chromatography (SPE-LC) interface for automated peptide separation and identification by tandem mass spectrometry , 2007 .

[19]  J. Nulsen,et al.  Effects of gonadotropin-releasing hormone agonists and antagonists on luteal function , 2007, Current opinion in obstetrics & gynecology.

[20]  Wilhelm Schänzer,et al.  Mass spectrometric identification of peptide hormones in doping-control analysis. , 2007, The Analyst.

[21]  B. Simons,et al.  Covalent protein immobilization on glass surfaces: application to alkaline phosphatase. , 2005, Journal of biotechnology.

[22]  J. Simard,et al.  Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. , 2005, Endocrine reviews.

[23]  Z. Kele,et al.  Electrospray mass spectrometry of hydrophobic compounds using dimethyl sulfoxide and dimethylformamide as solvents. , 2001, Rapid communications in mass spectrometry : RCM.

[24]  J. Arcadi.  Rapid drop in serum testosterone after bilateral subcapsular orchiectomy , 1992, Journal of surgical oncology.

[25]  Jing Zhang,et al.  Disulfide bond formation in peptides by dimethyl sulfoxide. Scope and applications , 1991 .

[26]  A. Schally,et al.  Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. , 1971, Biochemical and biophysical research communications.

[27]  T. Kusamran,et al.  Application of LC/MS – IT – TOF for Screening of WADA Prohibited Doping Peptides , 2018 .

[28]  J. Yates,et al.  The quadrupole ion trap mass spectrometer--a small solution to a big challenge. , 1997, Analytical biochemistry.

[29]  R. Casper.  Clinical uses of gonadotropin-releasing hormone analogues. , 1991, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[30]  G. Martz.  [Hormone therapy of prostate cancer]. , 1959, Oncologia.